Absence of glycochenodeoxycholic acid (GCDCA) in human bile is an indication of cholestasis: A 1H MRS study

NMR in Biomedicine

Volumn 22, Issue 5, 2009, Pages 471-479

  Ijare, Omkar B ^a   Bezabeh, Tedros ^a   Albiin, Nils ^b   Arnelo, Urban ^b   Bergquist, Annika ^b   Lindberg, Bo ^b   Smith, Ian C P ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bile acids; Cholangiogram; Cholestasis; Glycochenodeoxycholic acid; Glycodeoxycholic acid; Human bile; Magnetic resonance spectroscopy; Primary sclerosing cholangitis

Indexed keywords

BILE ACIDS; CHOLANGIOGRAM; CHOLESTASIS; GLYCOCHENODEOXYCHOLIC ACID; GLYCODEOXYCHOLIC ACID; HUMAN BILE; PRIMARY SCLEROSING CHOLANGITIS;

ACIDS; AMIDES; DIAGNOSIS; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE DETECTORS;

BODY FLUIDS;

BILE ACID; GLYCINE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; PHOSPHATIDYLCHOLINE; TAURINE; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILE; CELL DAMAGE; CHOLANGIOGRAPHY; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE QUANTUM FILTERED CORRELATED SPECTROSCOPY; ENZYME STRUCTURE; FEMALE; HUMAN; IMAGE DISPLAY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY; TOTAL CORRELATED SPECTROSCOPY;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; BILE; CHOLESTASIS; FEMALE; GLYCOCHENODEOXYCHOLIC ACID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROTONS;

EID: 68049084500     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1355     Document Type: Article

References (39)

1. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes, role of ATP depletion and cystosolic free calcium. J. Clin. Invest. 1993; 92: 17-24.
2. Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J. Hepatol. 2000; 32: 129-140.
3. Greim H, Czygan P, Schaffner F, Popper H. Determination of bile acids in needle biopsies of human liver. Biochem. Med. 1973; 8: 280-286.
4. Bucher BT, Feng X, Jeyabalan G, Zhang B, Shao L, Guo Z, Gellar DA. Glycodeoxycholate (GCDC) inhibits cytokine induced iNOS expression in rat hepatocytes. J. Surg. Res. 2006; 138: 15-21.
5. Utanohara S, Tsuji M, Momma S, Morio Y, Oguchi K. The effect of ursodeoxycholic acid-induced apoptosis in rat hepatocytes. Toxicology 2005; 214: 77-86.
6. Tsuchiya S, Tsuji M, Morio Y, Oguchi K. Involvement of endoplasmic reticulum in glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes. Toxicol. Lett. 2006; 166: 140-149.
7. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J. Pediatr. Gastroenterol. Nutr. 2005; 41: 235-243.
8. Azer SA, Coverdale SA, Byth K, Farell GC, Stacey NH. Sequential changes in serum levels of individual bile acids in patients with chronic cholestatic liver disease. J. Gastenterol. Hepatol. 1996; 11: 208-215.
9. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2006; 2: 52.
10. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004; 9: 1-31.
11. Abe K, Yoshimura H, Tanaka H, Fugita N, Hikita T, Sakoda S. Comparison of conventional and diffusion-weighted MRI and proton MR spectroscopy in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like events. Neuroradiology 2004; 46: 113-117.
12. Lindon JC, Nicholson JK, Holmes E, Everett JR. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn. Reson. 2000; 12: 289-320.
13. Khan SA, Cox IJ, Thillainayagam AV, Bansi DS, Thomas HC, TaylorRobinson SD. Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur. J. Gastroenterol. Hepatol. 2005; 17: 733-738.
14. Cox IJ, Sharif A, Cobbold FL, Thomas HC, Taylor-Robinson SD. Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. World J. Gastroenterol. 2006; 12: 4773-4783.
15. 1H NMR spectroscopy. Magn. Reson. Med. 2005; 53: 1441-1446.
16. Srivastava M, Jadegoud Y, Nagana Gowda GA, Sharma A, Kapoor VK, Khetrapal CL. An accurate method for the cholesterol analysis in bile. Anal. Lett. 2005; 38: 2135-2141.
17. 1H NMR spectroscopy. Magn. Reson. Med. 2006; 56: 738-744.
18. 1H NMR spectroscopy. Lipids 2006; 41: 591-603.
19. 13C NMR characterization and stereochemical assignments of bile acids in aqueous media. Lipids 2005; 40: 1031-1041.
20. 1H NMR spectroscopy. Lipids 2006; 41: 577-589.
21. Jansen PLM, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 2003; 23: 315-322.
22. Kipp H, Pichetshote N, Arias IM. Transporters on demand: intrahepatic pools of cananilcular ATP binding cassette transporters in rat liver. J. Biol. Chem. 2001; 276: 7218-7224.
23. Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets 2005; 5: 289-303.
24. Kullak-Ublack GA, Beuers U, Paumgartner G. Hepatobiliary transport. J. Hepatol. 2000; 32: 3-18.
25. Paumgartner G. Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J. Gastroenterol. 2006; 12: 4445-4451.
26. Tazawa Y, Yamada M, Nakagawa M, Konno T, Tada K. Bile acid profiles in siblings with progressive intrahepatic cholestasis: absence of biliary chenodeoxycholate. J. Pediatr. Gastroenterol. Nutr. 1985; 4: 32-37.
27. Jacquemin E, Dumont M, Bernard O, Erlinger S, Hadchouel M. Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease). Eur. J. Pediatr. 1994; 153: 424-428.
28. Kurbegov AC, Setchell KDR, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, Karrer F, Sokol RJ. Biliary diversion for progressive familial intrahepatic cholestasis: improve liver morphology and bile acid profile. Gastroenterology 2003; 125: 1227-1234.
29. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 40: 693-698.
30. Fedorowski T, Salen G, Colallilo A, Tint GS, Mosbach EH, Hall JC. Metabolism of ursodeoxycholic acid. Gastroenterology 1977; 73: 1131-1137.
31. Magnus CP, Kerb R, Fattinger K, Lang T, Anwald B, Ublick K, Beuers U, Meier PJ. BSEP and MDR3 haplotype structure in healthy caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004; 39: 779-791.
32. Rosmorduc O, Hermelin B, Boelle PY, Poupon RE, Poupon R, Chazouilleres O. ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 2004; 126: 1220-1222.
33. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin. Liver Dis. 2007; 27: 77-98.
34. Adachi T, Tajima Y, Kuroki T, Mishima T, Kitasato A, Fukuda K, Tsutsumi R, Kanematsu T. Bile-reflux into the pancreatic ducts is associated with the development of intraductal papillary carcinoma in hamsters. J. Surg. Res. 2006; 136: 106-111.
35. Sugiyama Y, Kobori H, Hakamada K, Seito D, Sasaki M. Altered bile composition in the gallbladder and common bile duct of patients with anomalous pancreaticobiliary ductal junction. World J. Surg. 2000; 24: 17-21.
36. Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 2006; 22: 209-214.
37. Lou YJ, Chen CX, Jiang JY, Li YM. Hepatobiliary and pancreatic: hemobilia. J. Gastroenterol. Hepatol. 2006; 21: 474.
38. 1H MR spectroscopy. Radiology 2003; 229: 587-592.
39. 1H magnetic resonance spectroscopy. Biochim. Biophys. Acta 2007; 1771: 544-549.